



Advancements in Bladder Cancer Therapy

Guest Editor:

**Prof. Dr. Jørgen Bjerggaard
Jensen**

Department of Clinical Medicine -
Department of Urology, Palle
Juul-Jensens, Boulevard 35, 8200
Aarhus N, Denmark

Deadline for manuscript
submissions:

31 May 2025

Message from the Guest Editor

The field of bladder cancer has attracted significant attention in recent years with the introduction of new systemic therapy not only for metastatic disease but also for localized and non-muscle invasive disease. Moreover, molecular medicine and genetics are making impressive progress in the diagnostic and prognostic field. With both new treatment modalities and new diagnostic individualized work-up, we must rethink the whole field of bladder cancer surgery and treatment regimens. This Special Issue of *Cancers* will focus on both potential upcoming changes in regimens based on new diagnostics but also on new treatment strategies with a multimodal and individualized approach together with new emerging therapies in an otherwise well-known disease.

Prof. Dr. Jørgen Jensen
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)